U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C30H27N5O.2CH4O3S.H2O
Molecular Weight 683.795
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BMS-833923 DIMESYLATE MONOHYDRATE

SMILES

O.CS(O)(=O)=O.CS(O)(=O)=O.CNCC1=CC(NC(=O)C2=CC=C(NC3=NC4=CC=CC=C4C(=N3)C5=CC=CC=C5)C=C2)=C(C)C=C1

InChI

InChIKey=UYMWHMMVNCGRHJ-UHFFFAOYSA-N
InChI=1S/C30H27N5O.2CH4O3S.H2O/c1-20-12-13-21(19-31-2)18-27(20)33-29(36)23-14-16-24(17-15-23)32-30-34-26-11-7-6-10-25(26)28(35-30)22-8-4-3-5-9-22;2*1-5(2,3)4;/h3-18,31H,19H2,1-2H3,(H,33,36)(H,32,34,35);2*1H3,(H,2,3,4);1H2

HIDE SMILES / InChI
Molecular Formula C30H27N5O
Molecular Weight 473.5683
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula CH4O3S
Molecular Weight 96.106
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24105601 | http://drugprofiles.informa.com/drug_profiles/14075-bms-833923

BMS-833923 was discovered by Exelixis and was out-licensed to Bristol-Myers Squibb. BMS-833923 is an orally bioavailable Smoothened antagonist. BMS-833923 reduces hedgehog pathway activity, decreases cell proliferation and induces apoptosis via the intrinsic pathway in esophageal adenocarcinoma (EAC) cell lines. BMS-833923 dose-dependently affects canonical and prostate hedgehog signature gene transcription in vitro. BMS-833923 is in phase II clinical trials for the treatment of chronic myeloid leukaemia.

Originator

Exelixis
25
Curator's Comment: BMS-833923 was discovered by Exelixis and was out-licensed to Bristol-Myers Squibb. # Exelixis

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 21.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
102 ng/mL
EXPERIMENT
https://doi.org/10.1158/1535-7163.TARG-09-A55
120 mg 1 times / day multiple, oral
dose: 120 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BMS-833923 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7 day
EXPERIMENT
https://doi.org/10.1158/1535-7163.TARG-09-A55
120 mg 1 times / day multiple, oral
dose: 120 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BMS-833923 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY34211
https://www.001chemical.com/chem/search?q=DY34211
1PlusChem LLC
1P008TVA
https://www.1pchem.com/search?query=1P008TVA
Aceschem
ACS019846
https://www.aceschem.com/catalog/search.do?q=ACS019846
AChemBlock
10333
http://www.achemblock.com/catalogsearch/result/?q=10333
AK Scientific
2281AH
https://aksci.com/item_detail.php?cat=2281AH
Ambeed
A174690
http://www.ambeed.com/search/Search.html?keyword=A174690
Angene
AGN-PC-0WH9NX
http://www.angenechemical.com/productshow/AGN-PC-0WH9NX.html
AOBIOUS INC
AOB87352
http://aobious.com/aobious/search?search_query=AOB87352
ApexBio Technology
A3258
https://www.apexbt.com/catalogsearch/result/?q=A3258
AstaTech
40972
http://astatechinc.com/CPSResult.php?CRNO=40972
Axon MedChem
2356
https://www.axonmedchem.com/product/2356
BLD Pharm
BD559139
http://www.bldpharm.com/search/Search.html?keyword=BD559139
Capot Chemical
33970
https://www.capotchem.com/search.do?q=33970
Cayman Chemical
16240
http://www.caymanchem.com/app/template/Product.vm/catalog/16240
Chem Scene
CS-1464
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-1464
ChemShuttle
111952
https://www.chemshuttle.com/catalogsearch/result/?q=111952
Debye Scientific
DA-35015
https://www.debyesci.com/index.php?id=product&ext[cno]=DA-35015
eMolecules
49383486
https://orderbb.emolecules.com/search/#?query=49383486
eNovation Chemicals
D372431
https://www.enovationchem.com/Products.asp?SEARCHTEXT=D372431&searchbtn.x=0&searchbtn.y=0
Excenen
EX-A789
http://www.excenen.com/searchresultlist.php?id=EX-A789
Hairui
HR32999
http://www.hairuichem.com/en/product/search.do?q=HR32999
KeyOrganics
AS-56170
http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-56170
Matrix Scientific
147273
http://www.matrixscientific.com/147273.html
mcule
MCULE-2931196442
https://mcule.com/MCULE-2931196442/
MedChem Express
HY-13809
https://www.medchemexpress.com/search.html?q=HY-13809&ft=&fa=&fp=
Molcore
MC34211
http://www.molcore.com/CatMC34211.html
Molnova
M17789
https://www.molnova.com/en/serch-list.html?keywords=M17789
MolPort
MolPort-035-395-837
https://www.molport.com/shop/molecule-link/MolPort-035-395-837
MuseChem
I000303
https://www.musechem.com/product/I000303.html
PI Chemicals
PI-38379
http://www.pipharm.com/catalog_products/PI-38379.html
Ryan Scientific
Ibudilast
https://ryansci.com/products?q=Ibudilast&list_q=&search_type=exact
Selleck Chemicals
S7138
http://www.selleckchem.com/search.html?searchDTO.searchParam=S7138
ShangHai Biochempartner
BCP000921
http://www.biochempartner.com/search_BCP000921
ShangHai Biochempartner
BCP07837
http://www.biochempartner.com/search_BCP07837
TargetMol
T2299
https://www.targetmol.com/search?keyword=T2299
PubMed

PubMed

TitleDatePubMed
Hedgehog signaling is active in human prostate cancer stroma and regulates proliferation and differentiation of adjacent epithelium.
2013-12
Smoothened inhibition leads to decreased proliferation and induces apoptosis in esophageal adenocarcinoma cells.
2013-08
Emerging treatments and signaling pathway inhibitors.
2011-12
Patents

Patents

US20140309184
2
US20150045363
2
US8222263
2
US8754092
2

Sample Use Guides

In Vivo Use Guide
Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
Route of Administration: Oral
In Vitro Use Guide
BMS-833923 (10 uM) decreased cell proliferation of cholangiocellular carcinoma cell line (EGI-1) up to 89.4% compared to the control.
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:24:51 GMT 2025
Edited
by admin
on Mon Mar 31 21:24:51 GMT 2025
Record UNII
483ONS63WN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BMS-833923 DIMESYLATE MONOHYDRATE
Code English
N-(2-METHYL-5-((METHYL AMINO) METHYL) PHENYL)-4-(4-PHENYLQUINAZOLIN-2-YLAMINO) BENZAMIDE BISMESYLATE MONOHYDRATE
Preferred Name English
Code System Code Type Description
NCI_THESAURUS
C77861
Created by admin on Mon Mar 31 21:24:51 GMT 2025 , Edited by admin on Mon Mar 31 21:24:51 GMT 2025
PRIMARY
ChEMBL
CHEMBL3545403
Created by admin on Mon Mar 31 21:24:51 GMT 2025 , Edited by admin on Mon Mar 31 21:24:51 GMT 2025
PRIMARY
PUBCHEM
162623676
Created by admin on Mon Mar 31 21:24:51 GMT 2025 , Edited by admin on Mon Mar 31 21:24:51 GMT 2025
PRIMARY
FDA UNII
483ONS63WN
Created by admin on Mon Mar 31 21:24:51 GMT 2025 , Edited by admin on Mon Mar 31 21:24:51 GMT 2025
PRIMARY
Related Record Type Details
Structure of BMS-833923
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of BMS-833923
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966